STACK_RATINGSby NERD_PROTOCOLS
< LEADERBOARD/s/n-acetylcysteineSulfur compounds

N-Acetylcysteine

Also sold as: NAC · Acetylcysteine · N-acetyl-L-cysteine

A cysteine donor used medically as a mucolytic and as an acetaminophen antidote. Supplement research spans PCOS and psychiatric adjuncts, with substantial uncertainty outside established medical indications.

Anxiety

COMMUNITY_STACK_RATINGlive · n=0

Community

Not enough ratings yet: 0 of 10

Scores appear after 10 ratings, so that one or two reports can't dominate. Tried it? Your rating counts.

+ Rate your experience (30 sec, anonymous)

NERD_PROTOCOL // EVIDENCE_MATRIXper goal

Research

AnxietyNo established evidence
  • Anxiety: The dossier does not establish benefit for general anxiety. OCD-spectrum, psychosis and COPD findings must not be mapped to anxiety relief.

REALITY CHECK // NAC is an established medical antidote, but that does not validate consumer detox or hangover claims. Clinical adjunctive evidence varies by condition; psychiatric outcomes do not establish general anxiety relief, and preclinical tumor-progression concerns are not proof that NAC causes cancer in humans.

Levels: how we grade evidence. Grey = evidence of no benefit; amber = evidence it makes this goal worse.

Ratings are self-reported by a self-selected group of users: how it felt, not proof that it works.

CHECK_YOUR_BOTTLE.EXEruns in your browser · nothing is sent or stored

Check your bottle

Compare what your label says with what was used in trials. This is a trial range, not a personal prescription.

Try a common label:
The label number is the…

Enter the amount from your label to see the result.

How it was studied

01 // STUDIED_DOSE_RANGE
Trial exposure, not an individual prescription
The dossier describes oral supplement exposures of 600-1800 mg/day and clinical psychiatric trials up to 2400-3000 mg/day. COPD/chronic bronchitis evidence particularly concerns 1200 mg/day. Psychiatric trials use chronic adjunctive treatment, not an acute rescue dose. Hospital antidote regimens are deliberately excluded from the calculator.
02 // TIMING_&_MATRIX
Route and formulation matter
No optimal morning/evening or fasting schedule is established here. Compare full oral NAC mass; effervescence is not proven clinically superior and hospital IV/inhaled routes are separate.
03 // EVALUATION_WINDOW
Match the study window
Chronic adjunctive studies run weeks to months; psychosis signals can require months. Antidote treatment is an urgent medical pathway, not a self-evaluation window.
04 // SAFETY_&_QUALITY_GATE
Clinical review and label check
Review asthma/bronchial hyperreactivity, active peptic ulcer, pregnancy/lactation and pediatric use; inhaled NAC has a distinct bronchospasm risk. Cancer patients should consult their oncologist. Stop and seek assessment for wheeze, significant rash, faintness or persistent GI symptoms. Do not use OTC NAC to manage suspected acetaminophen overdose: seek urgent medical care.

UPPER LIMIT // No formal comparable EFSA/NIH supplement UL is verified. Studied doses up to 2400-3000 mg/day are not an established general safety ceiling. High-dose oral use mainly causes GI symptoms; IV treatment has a different risk profile and requires medical supervision.

NERD'S NOTENerd Protocols · a clinical and sports dietitian based in the EU

Summary

Medical antidote and mucolytic uses have separate clinical pathways. PCOS trials suggest adjunctive reproductive/metabolic benefits with heterogeneity; psychiatric and craving effects are small or inconsistent. It is not a stand-alone psychiatric treatment or a general detox supplement.

Mechanism

NAC supplies cysteine for glutathione synthesis, has thiol-mediated mucus effects and modulates glutamatergic pathways. Low oral parent-drug availability does not mean no biological action; mechanism does not establish broad clinical efficacy.

Typical studied dose

The dossier describes oral supplement exposures of 600-1800 mg/day and clinical psychiatric trials up to 2400-3000 mg/day. COPD/chronic bronchitis evidence particularly concerns 1200 mg/day. Psychiatric trials use chronic adjunctive treatment, not an acute rescue dose. Hospital antidote regimens are deliberately excluded from the calculator.

Upper limit

No formal comparable EFSA/NIH supplement UL is verified. Studied doses up to 2400-3000 mg/day are not an established general safety ceiling. High-dose oral use mainly causes GI symptoms; IV treatment has a different risk profile and requires medical supervision.

POPULAR_STACKScombos with n ≥ 5

Popular stacks with N-Acetylcysteine

Not enough stack data yet. A combination with N-Acetylcysteine appears here once 5 people rate the same set.

> Rate my stack

Forms and label traps

Forms compared
Form on labelActive contentStudied range / dayAbsorption & GI toleranceVerdict
Standard NAC capsules / tablets / powder
Best for: Identifying oral NAC study exposure across condition-specific trials.
 Extract weight · marker not quantified 600–3000 mg Parent NAC oral availability about 4-10%, with substantial first-pass metabolism; compare full labeled NAC mass.
Nausea, reflux, diarrhea and sulfurous belching can occur.		 Studied standard [FORM // REFERENCE]
This broad dossier interval spans different indications; it is not one effective target or prescription. Do not multiply/divide dose by bioavailability.
Effervescent oral NAC
Best for: Label comparison of oral NAC, not hospital formulations.
 Extract weight · marker not quantified 600–3000 mg Dissolution differs, but clinically superior chronic efficacy is not demonstrated.
Dilution may help some people; no established general superiority.		 Good option [FORM // GOOD]
Whole NAC mg is the comparison basis. Range is the same-molecule oral dossier interval, not an effervescent-specific efficacy result.
NAC ethyl ester (NACET)
Best for: Research context only.
 Unstandardized: active content unknown no comparable trial range More lipophilic experimental derivative; no established equivalent human dose.
Human safety/tolerability insufficiently indexed.		 Avoid / not comparable [FORM // AVOID]
Do not treat it as a dose-equivalent, superior consumer NAC.
GlyNAC: glycine plus NAC
Best for: Checking separate glycine and NAC amounts.
 Unstandardized: active content unknown no comparable trial range Two glutathione precursors; preliminary combination research.
Combined-component tolerability depends on actual doses.		 Caution [FORM // CAUTION]
No single total-mixture mg target or proven anti-aging conversion is supported.

Common label traps

  • TRAP_01 // A POWERFUL UNIVERSAL DETOX
    Hospital acetaminophen antidote efficacy is time-dependent and indication-specific; it does not prove toxin or heavy-metal cleansing in healthy users.
  • TRAP_02 // NAC ALONE TREATS OCD OR ANXIETY
    Psychiatric research is adjunctive, mixed and diagnosis-specific. Do not replace therapy or prescribed medicines.
  • TRAP_03 // NAC CAUSES CANCER / IS COMPLETELY HARMLESS
    Tumor-progression concerns are mainly preclinical and unresolved in humans; cancer therapy needs oncologist review.
  • TRAP_04 // NAC ROUTINELY PROTECTS KIDNEYS FROM CONTRAST
    Early small-study benefit signals were not consistently confirmed by larger/higher-quality evidence; it is not a DIY contrast-protection protocol.
  • TRAP_05 // GLYNAC REVERSES AGING OR PREVENTS HANGOVERS
    The dossier does not establish these marketing claims.

Other outcomes studied

Outside the five leaderboard goals. Same evidence levels as above.

  • Acetaminophen poisoning: medical context Strong · benefit
    Early hospital treatment, ideally within 8-10 hours, is highly effective and time-sensitive. Reviews comparing two- versus three-bag IV regimens report comparable effectiveness and fewer anaphylactoid reactions with two bags. This is not a home supplement protocol.
    PMID 40013897 PMID 36034775 PMID 38165196
  • PCOS adjunct Moderate · benefit
    Meta-analyses suggest improved ovulation/pregnancy outcomes and heterogeneous metabolic/hormonal effects in women with PCOS. Variable comparisons and high heterogeneity preclude first-line or universal claims.
    PMID 39861414 PMID 36597797 PMID 37841396 PMID 34592079 PMID 39039898
  • Male fertility Limited · benefit
    Antioxidant literature suggests semen-parameter changes with low certainty; biomarker improvement is not established live-birth benefit.
    PMID 28717270
  • OCD-spectrum adjunct Limited · benefit
    Some adult trichotillomania trials are positive; OCD trials are inconsistent and small. Studied doses 2400-3000 mg/day require specialist review; pediatric evidence is weaker.
    PMID 34582562 PMID 30892151 PMID 25957927
  • Psychosis adjunct Limited · benefit
    Meta-analyses show small general/negative-symptom changes over months when added to treatment, not NAC monotherapy.
    PMID 37712506 PMID 29457216 PMID 31826654
  • Depression adjunct Limited · benefit
    Reviews conflict: some show small adjunctive benefits, others are inconclusive/null. Effects, if present, emerge over weeks to months; do not infer established general anxiety benefit.
    PMID 32767039 PMID 39504621 PMID 29457216
  • Substance-use craving Limited · benefit
    Small craving reductions are reported, but cannabis-use pharmacotherapy evidence remains uncertain and sustained abstinence is not established.
    PMID 39556483 PMID 39309000 PMID 28898494 PMID 41025421
  • Chronic bronchitis / COPD Moderate · benefit
    Mucolytic reviews suggest modest reductions in exacerbations/disability days, particularly with NAC 1200 mg/day. Dose, disease context and study heterogeneity matter; this is not anxiety evidence.
    PMID 38555190 PMID 39413571 PMID 31107966 PMID 26324807
  • Contrast-associated kidney injury prophylaxis Limited · no benefit
    Early small studies and reviews suggested benefit; larger/higher-quality evidence and later analyses do not consistently support added benefit over hydration. Do not self-prescribe prophylaxis.
    PMID 16368307 PMID 26830221 PMID 35636024 PMID 26458505
  • Fatty liver disease Limited · benefit
    Small inconsistent biochemical signals in adults/children do not establish histologic benefit or justify routine use for NAFLD/MASLD.
    PMID 19412008

Reader questions

What dose should I use for OCD?

The dossier reports 2400-3000 mg/day in some clinical studies, with mixed results and specialist supervision. That is evidence context, not a home treatment instruction.

Can it cause cancer?

Preclinical progression signals do not prove cancer causation in humans. Existing cancer or active treatment requires oncologist review.

Is NAC the same as L-cysteine or NACET?

They are different molecules/formulations; NAC is a cysteine donor, and NACET is an experimental derivative with no established equivalent consumer dose.

With food, morning or evening?

An optimal schedule is not established in the extracted evidence. Tolerability and medicine-specific directions matter more than unsupported timing claims.

Does NAC cause dependence or emotional blunting?

Dependence/withdrawal is not established in this dossier. Emotional blunting is an anecdotal concern; discuss persistent mood changes and do not alter psychiatric treatment yourself.

Stack interactions

  • Caution Nitroglycerin / nitrates [CAUTION // REVIEW_CONTEXT]
    The dossier reports amplified vasodilation, headaches and hypotension but lacks a linked primary citation; obtain medication review before combining.
  • Caution Anticoagulants / antiplatelets [CAUTION // REVIEW_CONTEXT]
    Platelet/NO mechanisms suggest a possible additive effect; clinical magnitude is unverified.
  • Caution Cancer therapy [CAUTION // REVIEW_CONTEXT]
    Antioxidant effects may conflict with some treatment mechanisms, and tumor-progression concerns are mainly preclinical; use only with oncology review.
  • Caution Psychiatric medicines [CAUTION // REVIEW_CONTEXT]
    Adjunctive trials require clinical supervision; do not use NAC to independently taper antidepressants or benzodiazepines.
  • Caution Glycine, minerals and activated charcoal [CAUTION // REVIEW_CONTEXT]
    Glycine provides another glutathione precursor, but clinical synergy is not established here. Mineral chelation/charcoal adsorption are mechanistic cautions; the dossier suggests about two-hour mineral separation without direct clinical confirmation.

Red flags: interactions and who should avoid it

Interactions

Nitroglycerin vasodilation may be amplified, causing headache/hypotension; the extracted dossier lacks its direct citation. Antiplatelet/anticoagulant and glucose-lowering interactions are primarily theoretical. Review psychiatric co-treatment and cancer therapy with the treating specialist. Metal chelation and activated-charcoal adsorption are mechanistic cautions, not quantified supplement interaction trials.

Avoid or ask a doctor first if

Review asthma/bronchial hyperreactivity, active peptic ulcer, pregnancy/lactation and pediatric use; inhaled NAC has a distinct bronchospasm risk. Cancer patients should consult their oncologist. Stop and seek assessment for wheeze, significant rash, faintness or persistent GI symptoms. Do not use OTC NAC to manage suspected acetaminophen overdose: seek urgent medical care.

Sources (PubMed, 32)

  1. Comparison of two-bag and three-bag acetylcysteine regimens in the treatment of paracetamol poisoning: a systematic review and meta-analysis.
    PMID 40013897 · 2025 · Systematic review and meta-analysis
    Early hospital treatment, ideally within 8-10 hours, is highly effective and time-sensitive. Reviews comparing two- versus three-bag IV regimens report comparable effectiveness and fewer anaphylactoid reactions with two bags. This is not a home supplement protocol.
  2. N-Acetylcysteine for Preventing Acetaminophen-Induced Liver Injury: A Comprehensive Review.
    PMID 36034775 · 2022 · Systematic review and meta-analysis
    Early hospital treatment, ideally within 8-10 hours, is highly effective and time-sensitive. Reviews comparing two- versus three-bag IV regimens report comparable effectiveness and fewer anaphylactoid reactions with two bags. This is not a home supplement protocol.
  3. Is Two Better Than Three? A Systematic Review of Two-bag Intravenous N-acetylcysteine Regimens for Acetaminophen Poisoning.
    PMID 38165196 · 2023 · Systematic review and meta-analysis
    Early hospital treatment, ideally within 8-10 hours, is highly effective and time-sensitive. Reviews comparing two- versus three-bag IV regimens report comparable effectiveness and fewer anaphylactoid reactions with two bags. This is not a home supplement protocol.
  4. Efficacy of N-Acetylcysteine in Polycystic Ovary Syndrome: Systematic Review and Meta-Analysis.
    PMID 39861414 · 2025 · Systematic review and meta-analysis
    Meta-analyses suggest improved ovulation/pregnancy outcomes and heterogeneous metabolic/hormonal effects in women with PCOS. Variable comparisons and high heterogeneity preclude first-line or universal claims.
  5. The effects of N-acetylcysteine on ovulation and sex hormones profile in women with polycystic ovary syndrome: a systematic review and meta-analysis.
    PMID 36597797 · 2023 · Systematic review and meta-analysis
    Meta-analyses suggest improved ovulation/pregnancy outcomes and heterogeneous metabolic/hormonal effects in women with PCOS. Variable comparisons and high heterogeneity preclude first-line or universal claims.
  6. The effects of N-acetylcysteine supplement on metabolic parameters in women with polycystic ovary syndrome: a systematic review and meta-analysis.
    PMID 37841396 · 2023 · Systematic review and meta-analysis
    Meta-analyses suggest improved ovulation/pregnancy outcomes and heterogeneous metabolic/hormonal effects in women with PCOS. Variable comparisons and high heterogeneity preclude first-line or universal claims.
  7. N-acetyl-cysteine as adjuvant therapy in female infertility: a systematic review and meta-analysis.
    PMID 34592079 · 2020 · Systematic review and meta-analysis
    Meta-analyses suggest improved ovulation/pregnancy outcomes and heterogeneous metabolic/hormonal effects in women with PCOS. Variable comparisons and high heterogeneity preclude first-line or universal claims.
  8. A review of antioxidant N-acetylcysteine in addressing polycystic ovary syndrome.
    PMID 39039898 · 2024 · Systematic review and meta-analysis
    Meta-analyses suggest improved ovulation/pregnancy outcomes and heterogeneous metabolic/hormonal effects in women with PCOS. Variable comparisons and high heterogeneity preclude first-line or universal claims.
  9. Antioxidant therapy in idiopathic oligoasthenoteratozoospermia.
    PMID 28717270 · 2017 · Narrative review
    Antioxidant literature suggests semen-parameter changes with low certainty; biomarker improvement is not established live-birth benefit.
  10. Pharmacotherapy for trichotillomania.
    PMID 34582562 · 2021 · Systematic review and meta-analysis
    Some adult trichotillomania trials are positive; OCD trials are inconsistent and small. Studied doses 2400-3000 mg/day require specialist review; pediatric evidence is weaker.
  11. Drug Treatment of Trichotillomania (Hair-Pulling Disorder), Excoriation (Skin-picking) Disorder, and Nail-biting (Onychophagia).
    PMID 30892151 · 2019 · Systematic review and meta-analysis
    Some adult trichotillomania trials are positive; OCD trials are inconsistent and small. Studied doses 2400-3000 mg/day require specialist review; pediatric evidence is weaker.
  12. Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review.
    PMID 25957927 · 2015 · Systematic review and meta-analysis
    Some adult trichotillomania trials are positive; OCD trials are inconsistent and small. Studied doses 2400-3000 mg/day require specialist review; pediatric evidence is weaker.
  13. Efficacy and acceptability of adjunctive n-acetylcysteine for psychotic disorders: Systematic review and meta-analysis.
    PMID 37712506 · 2024 · Systematic review and meta-analysis
    Meta-analyses show small general/negative-symptom changes over months when added to treatment, not NAC monotherapy.
  14. N-acetylcysteine for major mental disorders: a systematic review and meta-analysis of randomized controlled trials.
    PMID 29457216 · 2018 · Systematic review and meta-analysis
    Meta-analyses show small general/negative-symptom changes over months when added to treatment, not NAC monotherapy. Reviews conflict: some show small adjunctive benefits, others are inconclusive/null. Effects, if present, emerge over weeks to months; do not infer established general anxiety benefit.
  15. Meta-analysis of randomised controlled trials with N-acetylcysteine in the treatment of schizophrenia.
    PMID 31826654 · 2020 · Systematic review and meta-analysis
    Meta-analyses show small general/negative-symptom changes over months when added to treatment, not NAC monotherapy.
  16. N-acetylcysteine as an adjunctive treatment for bipolar depression and major depressive disorder: a systematic review and meta-analysis of double-blind, randomized placebo-controlled trials.
    PMID 32767039 · 2020 · Systematic review and meta-analysis
    Reviews conflict: some show small adjunctive benefits, others are inconclusive/null. Effects, if present, emerge over weeks to months; do not infer established general anxiety benefit.
  17. Efficacy of N-acetylcysteine for patients with depression: An updated systematic review and meta-analysis.
    PMID 39504621 · 2024 · Systematic review and meta-analysis
    Reviews conflict: some show small adjunctive benefits, others are inconclusive/null. Effects, if present, emerge over weeks to months; do not infer established general anxiety benefit.
  18. N-acetylcysteine as a treatment for substance use cravings: A meta-analysis.
    PMID 39556483 · 2024 · Systematic review and meta-analysis
    Small craving reductions are reported, but cannabis-use pharmacotherapy evidence remains uncertain and sustained abstinence is not established.
  19. Effect of N-acetylcysteine on craving in substance use disorders (SUD): a meta-analysis of randomized controlled trials.
    PMID 39309000 · 2024 · Systematic review and meta-analysis
    Small craving reductions are reported, but cannabis-use pharmacotherapy evidence remains uncertain and sustained abstinence is not established.
  20. N-acetylcysteine in the treatment of craving in substance use disorders: Systematic review and meta-analysis.
    PMID 28898494 · 2017 · Systematic review and meta-analysis
    Small craving reductions are reported, but cannabis-use pharmacotherapy evidence remains uncertain and sustained abstinence is not established.
  21. Pharmacotherapies for cannabis use disorder.
    PMID 41025421 · 2025 · Systematic review and meta-analysis
    Small craving reductions are reported, but cannabis-use pharmacotherapy evidence remains uncertain and sustained abstinence is not established.
  22. N-acetylcysteine Treatment in Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis/Pre-COPD: Distinct Meta-analyses.
    PMID 38555190 · 2024 · Systematic review and meta-analysis
    Mucolytic reviews suggest modest reductions in exacerbations/disability days, particularly with NAC 1200 mg/day. Dose, disease context and study heterogeneity matter; this is not anxiety evidence.
  23. Efficacy and safety of mucolytics in patients with stable chronic obstructive pulmonary disease: A systematic review and meta-analysis.
    PMID 39413571 · 2024 · Systematic review and meta-analysis
    Mucolytic reviews suggest modest reductions in exacerbations/disability days, particularly with NAC 1200 mg/day. Dose, disease context and study heterogeneity matter; this is not anxiety evidence.
  24. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease.
    PMID 31107966 · 2019 · Systematic review and meta-analysis
    Mucolytic reviews suggest modest reductions in exacerbations/disability days, particularly with NAC 1200 mg/day. Dose, disease context and study heterogeneity matter; this is not anxiety evidence.
  25. Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis.
    PMID 26324807 · 2015 · Systematic review and meta-analysis
    Mucolytic reviews suggest modest reductions in exacerbations/disability days, particularly with NAC 1200 mg/day. Dose, disease context and study heterogeneity matter; this is not anxiety evidence.
  26. N-acetylcysteine and contrast-induced nephropathy: a meta-analysis of 13 randomized trials.
    PMID 16368307 · 2006 · Systematic review and meta-analysis
    Early small studies and reviews suggested benefit; larger/higher-quality evidence and later analyses do not consistently support added benefit over hydration. Do not self-prescribe prophylaxis.
  27. Effectiveness of Prevention Strategies for Contrast-Induced Nephropathy: A Systematic Review and Meta-analysis.
    PMID 26830221 · 2016 · Systematic review and meta-analysis
    Early small studies and reviews suggested benefit; larger/higher-quality evidence and later analyses do not consistently support added benefit over hydration. Do not self-prescribe prophylaxis.
  28. Systematic review and meta-analysis of prophylaxis use with intravenous contrast exposure to prevent contrast-induced nephropathy.
    PMID 35636024 · 2022 · Systematic review and meta-analysis
    Early small studies and reviews suggested benefit; larger/higher-quality evidence and later analyses do not consistently support added benefit over hydration. Do not self-prescribe prophylaxis.
  29. N-acetylcysteine for the prevention of contrast-induced nephropathy in patients with pre-existing renal insufficiency or diabetes: a systematic review and meta-analysis.
    PMID 26458505 · 2015 · Systematic review and meta-analysis
    Early small studies and reviews suggested benefit; larger/higher-quality evidence and later analyses do not consistently support added benefit over hydration. Do not self-prescribe prophylaxis.
  30. Pharmacological interventions for nonalcoholic fatty liver disease in adults and in children: a systematic review.
    PMID 19412008 · 2009 · Systematic review and meta-analysis
    Small inconsistent biochemical signals in adults/children do not establish histologic benefit or justify routine use for NAFLD/MASLD.
  31. Pharmacokinetics and bioavailability of oral acetylcysteine in healthy volunteers.
    PMID 2757663 · 1989 · Randomized controlled trial
    Parent NAC oral availability about 4-10%, with substantial first-pass metabolism; compare full labeled NAC mass. This broad dossier interval spans different indications; it is not one effective target or prescription. Do not multiply/divide dose by bioavailability.
  32. Pharmacokinetics and bioavailability of reduced and oxidized N-acetylcysteine.
    PMID 3360052 · 1988 · Randomized controlled trial
    Parent NAC oral availability about 4-10%, with substantial first-pass metabolism; compare full labeled NAC mass. This broad dossier interval spans different indications; it is not one effective target or prescription. Do not multiply/divide dose by bioavailability.

Community comments

No approved comments yet. Comments are held for moderation.

+ Rate this